Literature DB >> 7647014

The gp 130 family cytokines IL-6, LIF and OSM but not IL-11 can reverse the anti-proliferative effect of dexamethasone on human myeloma cells.

N Juge-Morineau1, S François, D Puthier, A Godard, R Bataille, M Amiot.   

Abstract

In order to understand the mechanisms supporting steroid escape in patients with multiple myeloma (MM), three IL-6 autocrine human myeloma cell lines, LP1, OPM2 and L363, have been treated with dexamethasone in the presence or absence of cytokines belonging to the gp 130 family: IL-6, LIF, OSM and IL-11. With pharmacological doses of dexamethasone, a dramatic growth arrest was observed in all the cell lines. IL-6 completely reversed this inhibition. Of note, this IL-6 induced reversion was still seen with very low amounts of IL-6 (12 pg/ml). Finally, whereas LIF and OSM had clear growth-promoting effects on OPM2 only, both cytokines (but not IL-11) reversed the dexamethasone-induced growth arrest in all the cell lines. Therefore the high levels of IL-6 (ng/ml) observed in the MM intermediate milieu and the putative presence of LIF and OSM can easily counteract the effects of dexamethasone in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7647014     DOI: 10.1111/j.1365-2141.1995.tb05605.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.

Authors:  Peter M Voorhees; Robert F Manges; Pieter Sonneveld; Sundar Jagannath; George Somlo; Amrita Krishnan; Suzanne Lentzsch; Richard C Frank; Sonja Zweegman; Pierre W Wijermans; Robert Z Orlowski; Britte Kranenburg; Brett Hall; Tineke Casneuf; Xiang Qin; Helgi van de Velde; Hong Xie; Sheeba K Thomas
Journal:  Br J Haematol       Date:  2013-02-25       Impact factor: 6.998

Review 2.  Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.

Authors:  Timothy R Rosean; Van S Tompkins; Guido Tricot; Carol J Holman; Alicia K Olivier; Fenghuang Zhan; Siegfried Janz
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

Review 3.  IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation.

Authors:  B E Barton
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

4.  CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging.

Authors:  Gary A Ulaner; Nicholas B Sobol; Joseph A O'Donoghue; Assen S Kirov; Christopher C Riedl; Ryan Min; Eric Smith; Lukas M Carter; Serge K Lyashchenko; Jason S Lewis; C Ola Landgren
Journal:  Radiology       Date:  2020-04-07       Impact factor: 11.105

5.  Leukemia inhibitory factor (LIF) modulates pro-opiomelanocortin (POMC) gene regulation in stably transfected AtT-20 cells overexpressing LIF.

Authors:  Q L Li; H Yano; S G Ren; X Li; T C Friedman; S Melmed
Journal:  Endocrine       Date:  1997-12       Impact factor: 3.633

6.  Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.

Authors:  Peter M Voorhees; Qing Chen; George W Small; Deborah J Kuhn; Sally A Hunsucker; Jeffrey A Nemeth; Robert Z Orlowski
Journal:  Br J Haematol       Date:  2008-03-06       Impact factor: 6.998

7.  Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse.

Authors:  K Vanderkerken; C De Greef; K Asosingh; B Arteta; M De Veerman; I Vande Broek; I Van Riet; M Kobayashi; B Smedsrod; B Van Camp
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.